Serotonin2c receptor constitutive activity: In vivo direct and indirect evidence and functional significance

Central Nervous System Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 98-107

  Navailles, Sylvia ^a   Lagière, Mélanie ^a   Guthrie, Martin ^a   De Deurwaerdère, Philippe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

5 HT2C receptor; Basal ganglia; c Fos expression; Constitutive activity; Dopamine release; Motoneuron excitability; Orofacial activity; Rabbit head bobs

Indexed keywords

1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 1, 2, 3, 5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL) PYRROLO [2, 3 F] INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2, 5 DIMETHOXYAMPHETAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; 5, 7 DIHYDROXYTRYPTAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL) OXY] 5 PYRIDYL] CARBAMOYL] INDOLINE; CLOZAPINE; COCAINE; CYPROHEPTADINE; DOPAMINE; DOPAMINE 2 RECEPTOR; EPLIVANSERIN; HALOPERIDOL; INOSITOL PHOSPHATE; KETANSERIN; MESULERGINE; MORPHINE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PROTEIN C FOS; S 32006; SDZ SER082; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE; SEROTONIN; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST;

BASAL GANGLION; BINDING AFFINITY; DOPAMINERGIC NERVE CELL; HUMAN; IMPULSIVENESS; LOCOMOTION; MUSCLE SPASM; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SPINAL CORD INJURY; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DRUG EFFECT; GENE EXPRESSION REGULATION; HEAD MOVEMENT; MENTAL DISEASE; METABOLISM; MOTONEURON; NERVE CELL NETWORK; ONCOGENE; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; RAT; SEROTONINERGIC NERVE CELL; SPECIES DIFFERENCE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; GENES, FOS; HEAD MOVEMENTS; HUMANS; IMPULSIVE BEHAVIOR; MENTAL DISORDERS; MOTOR NEURONS; NERVE NET; RABBITS; RATS; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONERGIC NEURONS; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SPECIES SPECIFICITY; SPINAL CORD INJURIES;

EID: 84885666367     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524911313020002     Document Type: Review

References (117)

1. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav., 2002, 71(4), 533-554.
2. Pazos, A.; Cortes, R.; Palacios, J. M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res., 1985, 346(2), 231-249.
3. Giorgetti, M.; Tecott, L. H. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol., 2004, 488(1-3), 1-9.
4. Tecott, L. H.; Sun, L. M.; Akana, S. F.; Strack, A. M.; Lowenstein, D. H.; Dallman, M. F.; Julius, D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature, 1995, 374(6522), 542-546.
5. Cryan, J. F.; Lucki, I. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J. Pharmacol. Exp. Ther., 2000, 295(3), 1120-1126.
6. Dekeyne, A.; Mannoury la Cour, C.; Gobert, A.; Brocco, M.; Lejeune, F.; Serres, F.; Sharp, T.; Daszuta, A.; Soumier, A.; Papp, M.; Rivet, J. M.; Flik, G.; Cremers, T. I.; Muller, O.; Lavielle, G.; Millan, M. J. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl), 2008, 199(4), 549-568.
7. Dekeyne, A.; Millan, M. J. Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization. Psychopharmacology (Berl), 2009, 203(2), 329-341.
8. Dunlop, J.; Marquis, K. L.; Lim, H. K.; Leung, L.; Kao, J.; Cheesman, C.; Rosenzweig-Lipson, S. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev., 2006, 12(3-4), 167-177.
9. Dunlop, J.; Sabb, A. L.; Mazandarani, H.; Zhang, J.; Kalgaonker, S.; Shukhina, E.; Sukoff, S.; Vogel, R. L.; Stack, G.; Schechter, L.; Harrison, B. L.; Rosenzweig-Lipson, S. WAY-163909 [(7bR, 10aR)-1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta-[b][1, 4]diazepino[6, 7, 1hi]indol e], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J. Pharmacol. Exp. Ther., 2005, 313(2), 862-869.
10. Marquis, K. L.; Sabb, A. L.; Logue, S. F.; Brennan, J. A.; Piesla, M. J.; Comery, T. A.; Grauer, S. M.; Ashby, C. R., Jr.; Nguyen, H. Q.; Dawson, L. A.; Barrett, J. E.; Stack, G.; Meltzer, H. Y.; Harrison, B. L.; Rosenzweig-Lipson, S. WAY-163909 [(7bR, 10aR)-1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta-[b][1, 4]diazepino[6, 7, 1hiindole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J. Pharmacol. Exp. Ther., 2007, 320(1), 486-496.
11. McCreary, A. C.; Cunningham, K. A. Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology, 1999, 20(6), 556-564.
12. Rocha, B. A.; Goulding, E. H.; O'Dell, L. E.; Mead, A. N.; Coufal, N. G.; Parsons, L. H.; Tecott, L. H. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J. Neurosci., 2002, 22(22), 10039-10045.
13. Rosenzweig-Lipson, S.; Sabb, A.; Stack, G.; Mitchell, P.; Lucki, I.; Malberg, J. E.; Grauer, S.; Brennan, J.; Cryan, J. F.; Sukoff Rizzo, S. J.; Dunlop, J.; Barrett, J. E.; Marquis, K. L. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl), 2007, 192(2), 159-170.
14. Bubar, M. J.; Cunningham, K. A. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr. Top. Med. Chem., 2006, 6(18), 1971-1985.
15. Millan, M. J. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie, 2005, 60(5), 441-460.
16. Schapira, A. H.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G. L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le Novere, N.; Obeso, J. A.; Schwarzschild, M. A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov., 2006, 5(10), 845-854.
17. Wood, M. D.; Reavill, C.; Trail, B.; Wilson, A.; Stean, T.; Kennett, G. A.; Lightowler, S.; Blackburn, T. P.; Thomas, D.; Gager, T. L.; Riley, G.; Holland, V.; Bromidge, S. M.; Forbes, I. T.; Middlemiss, D. N. SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology, 2001, 41(2), 186-199.
18. Berg, K. A.; Clarke, W. P.; Cunningham, K. A.; Spampinato, U. Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology, 2008, 55(6), 969-976.
19. Berg, K. A.; Stout, B. D.; Cropper, J. D.; Maayani, S.; Clarke, W. P. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol. Pharmacol., 1999, 55(5), 863-872.
20. Navailles, S.; De Deurwaerdère, P. The constitutive activity of 5-HT2C receptors as an additional modality of interaction of the serotonergic system in motor control. In 5-HT2C Receptors in the Pathophysiology of CNS Disease. Di Giovanni, G.; Di Matteo, V.; Esposito, E., Eds.; Springer, New York, 2010, Vol. 22; pp 187-214.
21. De Deurwaerdere, P.; Navailles, S.; Berg, K. A.; Clarke, W. P.; Spampinato, U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci., 2004, 24(13), 3235-3241.
22. Navailles, S.; Lagiere, M.; Roumegous, A.; Polito, M.; Boujema, M. B.; Cador, M.; Dunlop, J.; Chesselet, M. F.; Millan, M. J.; De Deurwaerdere, P. Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease. Int. J. Neuropsychopharmacol., 2013, 16(3), 1-14.
23. Scarlota, L. C.; Harvey, J. A.; Aloyo, V. J., The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B. Psychopharmacology (Berl), 2011, 213, (2-3), 393-401.
24. Murray, K. C.; Nakae, A.; Stephens, M. J.; Rank, M.; D'Amico, J.; Harvey, P. J.; Li, X.; Harris, R. L.; Ballou, E. W.; Anelli, R.; Heckman, C. J.; Mashimo, T.; Vavrek, R.; Sanelli, L.; Gorassini, M. A.; Bennett, D. J.; Fouad, K., Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat. Med., 2010, 16(6), 694-700.
25. Murray, K. C.; Stephens, M. J.; Ballou, E. W.; Heckman, C. J.; Bennett, D. J. Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity. J. Neurophysiol., 2011, 105(2), 731-748.
26. Berg, K. A.; Harvey, J. A.; Spampinato, U.; Clarke, W. P. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol. Sci., 2005, 26(12), 625-630.
27. De Deurwaerdere, P.; Spampinato, U. The nigrostriatal dopamine system: a neglected target for 5-HT2C receptors. Trends Pharmacol. Sci., 2001, 22(10), 502-504.
28. Berg, K. A.; Navailles, S.; Sanchez, T. A.; Silva, Y. M.; Wood, M. D.; Spampinato, U.; Clarke, W. P. Differential effects of 5-methyl-1-[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoro methylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses. J. Pharmacol. Exp. Ther., 2006, 319(1), 260-268.
29. Navailles, S.; De Deurwaerdere, P.; Spampinato, U. Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol. Psychiatry, 2006, 59(6), 568-575.
30. Wolf, W. A.; Schutz, L. J. The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J. Neurochem., 1997, 69(4), 1449-1458.
31. Barker, E. L.; Westphal, R. S.; Schmidt, D.; Sanders-Bush, E., Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem., 1994, 269(16), 11687-11690.
32. Herrick-Davis, K.; Grinde, E.; Teitler, M., Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther., 2000, 295(1), 226-232.
33. Lefkowitz, R. J.; Cotecchia, S.; Samama, P.; Costa, T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci., 1993, 14(8), 303-307.
34. Rauser, L.; Savage, J. E.; Meltzer, H. Y.; Roth, B. L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J. Pharmacol. Exp. Ther., 2001, 299(1), 83-89.
35. Schotte, A.; Janssen, P. F.; Megens, A. A.; Leysen, J. E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res., 1993, 631(2), 191-202.
36. Lucas, G.; De Deurwaerdere, P.; Caccia, S.; Umberto, S. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used. Neuropharmacology, 2000, 39(6), 1053-1063.
37. Navailles, S.; De Deurwaerdere, P.; Porras, G.; Spampinato, U. In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology, 2004, 29(2), 319-326.
38. Bubar, M. J.; Cunningham, K. A. Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience, 2007, 146(1), 286-297.
39. Bubar, M. J.; Stutz, S. J.; Cunningham, K. A. 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway. PloS one, 2011, 6(6), e20508.
40. Clemett, D. A.; Punhani, T.; Duxon, M. S.; Blackburn, T. P.; Fone, K. C. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology, 2000, 39(1), 123-132.
41. Eberle-Wang, K.; Mikeladze, Z.; Uryu, K.; Chesselet, M. F., Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J. Comp. Neurol., 1997, 384(2), 233-247.
42. Pompeiano, M.; Palacios, J. M.; Mengod, G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res. Mol. Brain Res., 1994, 23(1-2), 163-178.
43. Filip, M.; Cunningham, K. A. Serotonin 5-HT(2C) receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine. Pharmacol. Biochem. Behav., 2002, 71(4), 745-756.
44. Filip, M.; Cunningham, K. A. Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C) receptors in rat prefrontal cortex. J. Pharmacol. Exp. Ther., 2003, 306(2), 734-743.
45. Fletcher, P. J.; Chintoh, A. F.; Sinyard, J.; Higgins, G. A. Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine selfadministration. Neuropsychopharmacology, 2004, 29(2), 308-318.
46. De Deurwaerdère, P.; Mignon, L.; Chesselet, M. Physiological and pathophysiological aspects of 5-HT2C receptors in basal ganglia. In 5-HT2C Receptors in the Pathophysiology of CNS Disease. Di Giovanni, G.; Di Matteo, V.; Esposito, E., Eds.; Springer Science: New York, 2010; Vol. 22, pp. 351-382.
47. Alex, K. D.; Yavanian, G. J.; McFarlane, H. G.; Pluto, C. P.; Pehek, E. A. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse, 2005, 55(4), 242-251.
48. Leggio, G. M.; Cathala, A.; Neny, M.; Rouge-Pont, F.; Drago, F.; Piazza, P. V.; Spampinato, U. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. J. Neurochem., 2009, 111(2), 614-623.
49. Navailles, S.; Moison, D.; Ryczko, D.; Spampinato, U. Regiondependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors. J. Neurochem., 2006, 99(4), 1311-1319.
50. Navailles, S.; Moison, D.; Cunningham, K. A.; Spampinato, U. Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology, 2008, 33(2), 237-246.
51. Beyeler, A.; Kadiri, N.; Navailles, S.; Boujema, M. B.; Gonon, F.; Moine, C. L.; Gross, C.; De Deurwaerdere, P. Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia. Neuroscience, 2010, 169(1), 158-170.
52. De Deurwaerdere, P.; Chesselet, M. F. Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. J. Neurosci., 2000, 20(13), 5170-5178.
53. Gong, L.; Kostrzewa, R. M. Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol. Biochem. Behav., 1992, 41(3), 621-623.
54. Simansky, K. J.; Dave, K. D.; Inemer, B. R.; Nicklous, D. M.; Padron, J. M.; Aloyo, V. J.; Romano, A. G. A 5-HT2C agonist elicits hyperactivity and oral dyskinesia with hypophagia in rabbits. Physiol. Behav., 2004, 82(1), 97-107.
55. Stewart, B. R.; Jenner, P.; Marsden, C. D. Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. Eur. J. Pharmacol., 1989, 162(1), 101-107.
56. Wolf, W. A.; Bieganski, G. J.; Guillen, V.; Mignon, L. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology (Berl), 2005, 182(1), 84-94.
57. Eberle-Wang, K.; Lucki, I.; Chesselet, M. F. A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience, 1996, 72(1), 117-128.
58. Plech, A.; Brus, R.; Kalbfleisch, J. H.; Kostrzewa, R. M. Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology (Berl), 1995, 119(4), 466-473.
59. Navailles, S.; De Deurwaerdere, P. Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. Mol. Neurobiol., 2012, 45(1), 173-185.
60. Dave, K. D.; Harvey, J. A.; Aloyo, V. J. A novel behavioral model that discriminates between 5-HT2A and 5-HT2C receptor activation. Pharmacol. Biochem. Behav., 2002, 72(1-2), 371-378.
61. Harvey, P. J.; Li, X.; Li, Y.; Bennett, D. J. 5-HT2 receptor activation facilitates a persistent sodium current and repetitive firing in spinal motoneurons of rats with and without chronic spinal cord injury. J. Neurophysiol., 2006, 96(3), 1158-1170.
62. Rekling, J. C.; Funk, G. D.; Bayliss, D. A.; Dong, X. W.; Feldman, J. L. Synaptic control of motoneuronal excitability. Physiol. Rev., 2000, 80(2), 767-852.
63. Heckmann, C. J.; Gorassini, M. A.; Bennett, D. J. Persistent inward currents in motoneuron dendrites: implications for motor output. Muscle Nerve, 2005, 31(2), 135-156.
64. Li, X.; Murray, K.; Harvey, P. J.; Ballou, E. W.; Bennett, D. J. Serotonin facilitates a persistent calcium current in motoneurons of rats with and without chronic spinal cord injury. J. Neurophysiol., 2007, 97(2), 1236-1246.
65. Ung, R. V.; Landry, E. S.; Rouleau, P.; Lapointe, N. P.; Rouillard, C.; Guertin, P. A. Role of spinal 5-HT2 receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic spinal cord transection. Eur. J. Neurosci., 2008, 28(11), 2231-2242.
66. Gorassini, M. A.; Knash, M. E.; Harvey, P. J.; Bennett, D. J.; Yang, J. F. Role of motoneurons in the generation of muscle spasms after spinal cord injury. Brain, 2004, 127(Pt 10), 2247-2258.
67. Bennett, D. J.; Sanelli, L.; Cooke, C. L.; Harvey, P. J.; Gorassini, M. A. Spastic long-lasting reflexes in the awake rat after sacral spinal cord injury. J. Neurophysiol., 2004, 91(5), 2247-2258.
68. Li, Y.; Gorassini, M. A.; Bennett, D. J. Role of persistent sodium and calcium currents in motoneuron firing and spasticity in chronic spinal rats. J. Neurophysiol., 2004, 91(2), 767-783.
69. Kennett, G. A.; Wood, M. D.; Bright, F.; Cilia, J.; Piper, D. C.; Gager, T.; Thomas, D.; Baxter, G. S.; Forbes, I. T.; Ham, P.; Blackburn, T. P. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol., 1996, 117(3), 427-434.
70. De Deurwaerdere, P.; Le Moine, C.; Chesselet, M. F. Selective blockade of serotonin 2C receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia. Neurosci. Lett., 2010, 469(2), 251-255.
71. Kadiri, N.; Lagiere, M.; Le Moine, C.; Millan, M. J.; De Deurwaerdere, P.; Navailles, S. Diverse effects of 5-HT(2C) receptor blocking agents on c-Fos expression in the rat basal ganglia. Eur. J. Pharmacol., 2012, 689(1-3), 8-16.
72. Stark, J. A.; Davies, K. E.; Williams, S. R.; Luckman, S. M. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. Neuroimage, 2006, 31(3), 1228-1237.
73. Gardier, A. M.; Moratalla, R.; Cuellar, B.; Sacerdote, M.; Guibert, B.; Lebrec, H.; Graybiel, A. M. Interaction between the serotoninergic and dopaminergic systems in d-fenfluramineinduced activation of c-fos and jun B genes in rat striatal neurons. J. Neurochem., 2000, 74(4), 1363-1373.
74. Javed, A.; Van de Kar, L. D.; Gray, T. S. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Res., 1998, 791(1-2), 67-74.
75. Moorman, J. M.; Leslie, R. A. P-chloroamphetamine induces c-fos in rat brain: a study of serotonin2A/2C receptor function. Neuroscience, 1996, 72(1), 129-139.
76. Rouillard, C.; Bovetto, S.; Gervais, J.; Richard, D. Fenfluramineinduced activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. Brain Res. Mol. Brain Res., 1996, 37(1-2), 105-115.
77. Stark, J. A.; McKie, S.; Davies, K. E.; Williams, S. R.; Luckman, S. M. 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur. J. Neurosci., 2008, 27(2), 457-465.
78. Navailles, S.; De Deurwaerdere, P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl), 2011, 213(2-3), 213-242.
79. Belforte, J. E.; Pazo, J. H. Turning behaviour induced by stimulation of the 5-HT receptors in the subthalamic nucleus. Eur. J. Neurosci., 2004, 19(2), 346-355.
80. Mehta, A.; Eberle-Wang, K.; Chesselet, M. F. Increased m-CPPinduced oral dyskinesia after lesion of serotonergic neurons. Pharmacol. Biochem. Behav., 2001, 68(2), 347-353.
81. Fletcher, P. J.; Tampakeras, M.; Sinyard, J.; Higgins, G. A. Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology (Berl), 2007, 195(2), 223-234.
82. Winstanley, C. A.; Theobald, D. E.; Dalley, J. W.; Glennon, J. C.; Robbins, T. W. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl), 2004, 176(3-4), 376-385.
83. Carli, M.; Samanin, R. The 5-HT(1A) receptor agonist 8-OHDPAT reduces rats' accuracy of attentional performance and enhances impulsive responding in a five-choice serial reaction time task: role of presynaptic 5-HT(1A) receptors. Psychopharmacology (Berl), 2000, 149(3), 259-268.
84. Robinson, E. S.; Dalley, J. W.; Theobald, D. E.; Glennon, J. C.; Pezze, M. A.; Murphy, E. R.; Robbins, T. W. Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacol., 2008, 33(10), 2398-2406.
85. Talpos, J. C.; Wilkinson, L. S.; Robbins, T. W. A comparison of multiple 5-HT receptors in two tasks measuring impulsivity. J. Psychopharmacol., 2006, 20(1), 47-58.
86. Nozulak, J.; Kalkman, H. O.; Floersheim, P.; Hoyer, D.; Schoeffter, P.; Buerki, H. R. (+)-cis-4, 5, 7a, 8, 9, 10, 11, 11a-octahydro-7H-10-methylindolo[1, 7-bc][2, 6]-naphthyridine: a 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity. J. Med. Chem., 1995, 38(1), 28-33.
87. Martin, J. R.; Bos, M.; Jenck, F.; Moreau, J.; Mutel, V.; Sleight, A. J.; Wichmann, J.; Andrews, J. S.; Berendsen, H. H.; Broekkamp, C. L.; Ruigt, G. S.; Kohler, C.; Delft, A. M. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther., 1998, 286(2), 913-924.
88. Cussac, D.; Newman-Tancredi, A.; Quentric, Y.; Carpentier, N.; Poissonnet, G.; Parmentier, J. G.; Goldstein, S.; Millan, M. J. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedebergs Arch. Pharmacol., 2002, 365(3), 242-252.
89. Porter, R. H.; Benwell, K. R.; Lamb, H.; Malcolm, C. S.; Allen, N. H.; Revell, D. F.; Adams, D. R.; Sheardown, M. J. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol., 1999, 128(1), 13-20.
90. Diaz, S. L.; Doly, S.; Narboux-Neme, N.; Fernandez, S.; Mazot, P.; Banas, S. M.; Boutourlinsky, K.; Moutkine, I.; Belmer, A.; Roumier, A.; Maroteaux, L. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol. Psychiatry., 2012, 17(2), 154-163.
91. Auclair, A. L.; Cathala, A.; Sarrazin, F.; Depoortere, R.; Piazza, P. V.; Newman-Tancredi, A.; Spampinato, U. The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J. Neurochem., 2010, 114(5), 1323-1332.
92. Doly, S.; Bertran-Gonzalez, J.; Callebert, J.; Bruneau, A.; Banas, S. M.; Belmer, A.; Boutourlinsky, K.; Herve, D.; Launay, J. M.; Maroteaux, L. Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PloS one, 2009, 4(11), e7952.
93. Bevilacqua, L.; Doly, S.; Kaprio, J.; Yuan, Q.; Tikkanen, R.; Paunio, T.; Zhou, Z.; Wedenoja, J.; Maroteaux, L.; Diaz, S.; Belmer, A.; Hodgkinson, C. A.; Dell'osso, L.; Suvisaari, J.; Coccaro, E.; Rose, R. J.; Peltonen, L.; Virkkunen, M.; Goldman, D. A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature, 2010, 468(7327), 1061-1066.
94. Niswender, C. M.; Copeland, S. C.; Herrick-Davis, K.; Emeson, R. B.; Sanders-Bush, E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J. Biol. Chem., 1999, 274(14), 9472-9478.
95. Kenakin, T. P. Quantitation in receptor pharmacology. Receptors Channels, 2001, 7(5), 371-385.
96. Berg, K. A.; Dunlop, J.; Sanchez, T.; Silva, M.; Clarke, W. P. A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and-independent receptor signaling. J. Pharmacol. Exp. Ther., 2008, 324(3), 1084-1092.
97. Gardiner, K.; Du, Y. A-to-I editing of the 5HT2C receptor and behaviour. Brief. Funct. Genomic. Proteomic., 2006, 5, (1), 37-42.
98. O'Neil, R. T.; Emeson, R. B. Quantitative analysis of 5HT(2C) receptor RNA editing patterns in psychiatric disorders. Neurobiol. Dis, 2012, 45(1), 8-13.
99. Schmauss, C. Serotonin 2C receptors: suicide, serotonin, and runaway RNA editing. Neuroscientist, 2003, 9(4), 237-242.
100. Tohda, M.; Nomura, M.; Nomura, Y., Molecular pathopharmacology of 5-HT2C receptors and the RNA editing in the brain. J. Pharmacol. Sci., 2006, 100(5), 427-432.
101. Werry, T. D.; Loiacono, R.; Sexton, P. M.; Christopoulos, A., RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol. Ther., 2008, 119(1), 7-23.
102. Burns, C. M.; Chu, H.; Rueter, S. M.; Hutchinson, L. K.; Canton, H.; Sanders-Bush, E.; Emeson, R. B. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature, 1997, 387(6630), 303-308.
103. Niswender, C. M.; Sanders-Bush, E.; Emeson, R. B., Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann. N. Y. Acad. Sci., 1998, 861, 38-48.
104. Bhansali, P.; Dunning, J.; Singer, S. E.; David, L.; Schmauss, C. Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric Gprotein G q. J. Neurosci., 2007, 27(6), 1467-1473.
105. Englander, M. T.; Dulawa, S. C.; Bhansali, P.; Schmauss, C., How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J. Neurosci., 2005, 25(3), 648-651.
106. Gurevich, I.; Englander, M. T.; Adlersberg, M.; Siegal, N. B.; Schmauss, C. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J. Neurosci., 2002, 22(24), 10529-10532.
107. Gurevich, I.; Tamir, H.; Arango, V.; Dwork, A. J.; Mann, J. J.; Schmauss, C. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron, 2002, 34(3), 349-356.
108. Niswender, C. M.; Herrick-Davis, K.; Dilley, G. E.; Meltzer, H. Y.; Overholser, J. C.; Stockmeier, C. A.; Emeson, R. B.; Sanders-Bush, E. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacol., 2001, 24(5), 478-491.
109. Cussac, D.; Newman-Tancredi, A.; Duqueyroix, D.; Pasteau, V.; Millan, M. J. Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonistdirected trafficking. Mol. Pharmacol., 2002, 62(3), 578-589.
110. Price, R. D.; Weiner, D. M.; Chang, M. S.; Sanders-Bush, E. RNA editing of the human serotonin 5-HT2C receptor alters receptormediated activation of G13 protein. J. Biol. Chem., 2001, 276(48), 44663-44668.
111. Zhang, J. Y.; Kowal, D. M.; Nawoschik, S. P.; Lou, Z.; Dunlop, J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem. Pharmacol., 2006, 71(4), 521-529.
112. Kawahara, Y.; Grimberg, A.; Teegarden, S.; Mombereau, C.; Liu, S.; Bale, T. L.; Blendy, J. A.; Nishikura, K. Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J. Neurosci., 2008, 28(48), 12834-12844.
113. Kimura, A.; Stevenson, P. L.; Carter, R. N.; Maccoll, G.; French, K. L.; Paul Simons, J.; Al-Shawi, R.; Kelly, V.; Chapman, K. E.; Holmes, M. C. Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity. Eur. J. Neurosci., 2009, 30(2), 299-306.
114. Mombereau, C.; Kawahara, Y.; Gundersen, B. B.; Nishikura, K.; Blendy, J. A. Functional relevance of serotonin 2C receptor mRNA editing in antidepressant-and anxiety-like behaviors. Neuropharmacology, 2010, 59(6), 468-473.
115. Moya, P. R.; Fox, M. A.; Jensen, C. L.; Laporte, J. L.; French, H. T.; Wendland, J. R.; Murphy, D. L. Altered 5-HT2C receptor agonistinduced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. BMC pharmacology, 2011, 11, 3.
116. Knight, A. R.; Misra, A.; Quirk, K.; Benwell, K.; Revell, D.; Kennett, G.; Bickerdike, M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 370(2), 114-123.
117. Rinaldi-Carmona, M.; Congy, C.; Santucci, V.; Simiand, J.; Gautret, B.; Neliat, G.; Labeeuw, B.; Le Fur, G.; Soubrie, P.; Breliere, J. C. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J. Pharmacol. Exp. Ther., 1992, 262(2), 759-768.